Calesnick B
Hahnemann University School of Medicine, Philadelphia, Pennsylvania.
Am Fam Physician. 1990 Feb;41(2):589-91.
Monoamine oxidase inhibitors that have been available in the United States are nonselective and thus act equally on peripheral and brain monoamine oxidase. Recently, selegiline, a selective monoamine oxidase inhibitor, has been approved for use in the management of Parkinson's disease. Clinical trials demonstrate that selegiline in combination with carbidopa/levodopa is effective in relieving symptoms and prolonging remission. The dosage of carbidopa/levodopa can usually be reduced, resulting in diminished side effects. Selegiline is relatively nontoxic and appears to be a valuable addition in the management of Parkinson's disease.
在美国已上市的单胺氧化酶抑制剂是非选择性的，因此对周围和大脑的单胺氧化酶都有同等作用。最近，一种选择性单胺氧化酶抑制剂司来吉兰已被批准用于帕金森病的治疗。临床试验表明，司来吉兰与卡比多巴/左旋多巴联合使用可有效缓解症状并延长缓解期。卡比多巴/左旋多巴的剂量通常可以减少，从而减少副作用。司来吉兰相对无毒，似乎是帕金森病治疗中的一种有价值的辅助药物。
